TY - JOUR
T1 - Use of a screening tool to determine nonadherent behavior in inflammatory bowel disease
AU - Kane, Sunanda
AU - Becker, Brenda
AU - Harmsen, W. Scott
AU - Kurian, Ashok
AU - Morisky, Donald E.
AU - Zinsmeister, Alan R.
PY - 2012/2
Y1 - 2012/2
N2 - Objectives: Nonadherence is an issue in the management of inflammatory bowel disease (IBD), and no validated screening tool is available. We aimed to determine whether scores from a self-reported adherence survey correlated with pharmacy refill data as a reliable measure of medication adherence. Methods: We used the eight item, self-reported Morisky Medication Adherence Scale. Each question is worth a point, with a maximum score of 8. Pharmacies were contacted for refill information for the previous 3 months, then 3 and 6 months from enrollment. Refill data were recorded for each time interval as the medication possession ratio (MPR); adherence was defined as >80%. Analysis of variance was used to determine the relationship between survey scores and MPR by drug class. Results: One hundred fifty outpatients were enrolled, of whom 94 had Crohns disease and 56 had ulcerative colitis; 89 were female. At baseline, 47% of patients were on 5-aminosalicylic acid (5-ASA), 54% an immunomodulator, 15% infliximab, 8% an injectable biologic, and 6% budesonide. The median adherence score was 7. Fifty-two percent stated they rarely missed a dose of medication. The median adherence score, as defined by refill data, ranged from 0% (injectable biologic) to 75% (infliximab) by drug class. Only those on an immunomodulator had a survey score that positively correlated with adherence. Conclusions: Only those on a thiopurine were likely to have a score predicting adherence behavior. Adherence to therapy for IBD is complex and cannot be predicted reliably by a self-reported survey tool validated for other chronic conditions.
AB - Objectives: Nonadherence is an issue in the management of inflammatory bowel disease (IBD), and no validated screening tool is available. We aimed to determine whether scores from a self-reported adherence survey correlated with pharmacy refill data as a reliable measure of medication adherence. Methods: We used the eight item, self-reported Morisky Medication Adherence Scale. Each question is worth a point, with a maximum score of 8. Pharmacies were contacted for refill information for the previous 3 months, then 3 and 6 months from enrollment. Refill data were recorded for each time interval as the medication possession ratio (MPR); adherence was defined as >80%. Analysis of variance was used to determine the relationship between survey scores and MPR by drug class. Results: One hundred fifty outpatients were enrolled, of whom 94 had Crohns disease and 56 had ulcerative colitis; 89 were female. At baseline, 47% of patients were on 5-aminosalicylic acid (5-ASA), 54% an immunomodulator, 15% infliximab, 8% an injectable biologic, and 6% budesonide. The median adherence score was 7. Fifty-two percent stated they rarely missed a dose of medication. The median adherence score, as defined by refill data, ranged from 0% (injectable biologic) to 75% (infliximab) by drug class. Only those on an immunomodulator had a survey score that positively correlated with adherence. Conclusions: Only those on a thiopurine were likely to have a score predicting adherence behavior. Adherence to therapy for IBD is complex and cannot be predicted reliably by a self-reported survey tool validated for other chronic conditions.
UR - http://www.scopus.com/inward/record.url?scp=84856712025&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84856712025&partnerID=8YFLogxK
U2 - 10.1038/ajg.2011.317
DO - 10.1038/ajg.2011.317
M3 - Article
C2 - 22306937
AN - SCOPUS:84856712025
SN - 0002-9270
VL - 107
SP - 154
EP - 160
JO - American Journal of Gastroenterology
JF - American Journal of Gastroenterology
IS - 2
ER -